-

Varex to Present at Oppenheimer’s 32nd Annual Healthcare Virtual Investor Conference

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) announced today that it is scheduled to present at Oppenheimer’s 32nd Annual Healthcare virtual investor conference. Details are as follows:

Oppenheimer’s 32nd Annual Healthcare Conference
Varex will be presenting on Tuesday, March 15, 2022 at 2:40 pm ET.
The listen-only webcast link is: https://wsw.com/webcast/oppenheimer20/vrex/2821014

The company’s Chief Financial Officer, Sam Maheshwari, will provide an overview of Varex’s business. Varex’s presentation will be webcast and accessible to the public via the company's website at vareximaging.com. Replays will be available for 90 days after the presentation at the same website.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,100 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements using the terms “believe,” “expect,” “intend,” “future,” “anticipate,” “will,” “could,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varex’s actual results to differ materially from those anticipated. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. Such risks and uncertainties include global political and economic conditions, events, and hostilities; Varex’s ability to maintain compliance with our financial covenants; the continued impact of tariffs or a global trade war on Varex’s products and customer purchasing patterns; demand for and delays in delivery of products of Varex or its customers; Varex’s ability to develop, commercialize and deploy new products; the impact of reduced or limited demand by purchasers of certain X-ray products; the impact of competitive products and pricing; and the other risks listed from time to time in our filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. Any forward-looking statements made by us speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise.

Contacts

Christopher Belfiore
Director of Investor Relations
Varex Imaging Corporation
801.973.1566 | christopher.belfiore@vareximaging.com

Varex Imaging Corporation

NASDAQ:VREX

Release Summary
VAREX TO PRESENT AT OPPENHEIMER’S 32ND ANNUAL HEALTHCARE VIRTUAL INVESTOR CONFERENCE
Release Versions

Contacts

Christopher Belfiore
Director of Investor Relations
Varex Imaging Corporation
801.973.1566 | christopher.belfiore@vareximaging.com

More News From Varex Imaging Corporation

Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the fourth quarter and fiscal year 2025. Q4FY25 Summary Revenues $229 million GAAP gross margin 34% | Non-GAAP gross margin* 34% GAAP operating margin 9% | Non-GAAP operating margin* 10% GAAP net income $0.29 per diluted share | Non-GAAP net income* $0.37 per diluted share Cash flow from operations was $8 million FY25 Summary Revenues $845 million GAAP gross margin 34% |...

Varex Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the fourth quarter and fiscal year 2025, following the close of regular trading on Tuesday, November 18, 2025. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access...

Varex to Present at the Sidoti Small Cap Virtual Conference

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to present at the Sidoti Small Cap Virtual Conference. Management will be presenting on Wednesday, September 17, 2025 at 3:15pm ET. The webcast can be accessed here or on Varex’s website at www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors,...
Back to Newsroom